What is the recommended dose of Sevista (Ormeloxifene) for treating mastalgia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Dose of Sevista (Ormeloxifene) for Mastalgia

The recommended dose of Ormeloxifene (Sevista/Centchroman) for treating mastalgia is 30 mg orally once daily for 12 weeks, based on multiple clinical trials demonstrating significant pain reduction with this regimen. 1, 2

Standard Dosing Protocol

  • Initial treatment: 30 mg orally once daily for 12 weeks 3, 2
  • Alternative regimen: 30 mg on alternate days for 3 months has also been studied with good results 4
  • The once-daily regimen appears to provide faster and more consistent pain relief, particularly for cyclical mastalgia 2

Expected Treatment Response

  • Rapid onset: 90% of patients experience significant pain reduction (VAS score dropping from 10 to 3) within the first week of treatment 4
  • Complete response rates:
    • 66% for cyclical mastalgia at 1 week 2
    • 40% for noncyclical mastalgia at 1 week 2
    • 92% for cyclical mastalgia at 12 weeks 2
    • 80% for noncyclical mastalgia at 12 weeks 2
  • Overall response rate: 88% at 12 weeks, with sustained effect of 85% at 24 weeks post-treatment 2

Clinical Positioning

Ormeloxifene should be considered as first-line pharmacologic therapy for moderate to severe mastalgia after conservative measures (reassurance, proper bra fitting) have failed. 1, 2

  • It is more effective than topical NSAIDs for severe cases 1
  • Comparable efficacy to tamoxifen but with a different side effect profile 3
  • Particularly effective for cyclical mastalgia, with faster response than noncyclical patterns 2

Critical Safety Considerations and Side Effects

Important contraindications and monitoring requirements:

  • Common side effects include dizziness, menstrual irregularities, and development of ovarian cysts 3
  • Ovarian cyst development is a significant concern, occurring in a notable proportion of patients 3
  • Contraindicated in pregnancy, women planning pregnancy, and breastfeeding mothers (as with other SERMs) 5
  • Not recommended during prolonged immobilization or in patients with history of thromboembolic events (extrapolating from other SERM safety profiles) 5

Duration and Follow-up

  • Treatment duration: 12 weeks is the standard treatment period 3, 2
  • Post-treatment observation: Monitor for 12 weeks after cessation to assess sustained relief 3, 2
  • Partial relapse: Some patients may experience partial pain recurrence after stopping treatment, though many maintain significant improvement 3
  • Consider retreatment if symptoms recur after the observation period 2

Practical Implementation

Start with 30 mg once daily rather than alternate-day dosing for optimal results:

  • Once-daily dosing provides more consistent pain relief 2
  • Alternate-day dosing (30 mg every other day) may be considered if side effects occur with daily dosing 4
  • Monitor for ovarian cyst development with pelvic ultrasound if menstrual irregularities develop 3
  • Assess pain severity using Visual Analog Scale (VAS) at baseline, 1 week, 4 weeks, 12 weeks, and 24 weeks 2

Comparison to Alternative Treatments

Ormeloxifene offers advantages over traditional hormonal therapies:

  • Similar efficacy to tamoxifen 10 mg daily but with different side effect profile 3
  • Fewer androgenic or severe menopausal side effects compared to danazol 1
  • More effective than dopamine agonists for mastalgia 1
  • However, the frequency of ovarian cyst development is a significant concern that must be discussed with patients 3

Licensing and Availability Considerations

Note that Ormeloxifene is not licensed in all countries:

  • Currently used extensively in India for mastalgia treatment 1
  • Not licensed in the United Kingdom or United States as of the most recent evidence 1
  • Where unavailable, tamoxifen 10 mg daily remains the most effective alternative with established safety profile 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.